Prestige Consumer Healthcare Inc. $PBH Holdings Boosted by Brandes Investment Partners LP

Brandes Investment Partners LP boosted its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 93.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 606,737 shares of the company’s stock after purchasing an additional 292,744 shares during the period. Brandes Investment Partners LP’s holdings in Prestige Consumer Healthcare were worth $37,430,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $36,954,000. Nordea Investment Management AB grew its holdings in shares of Prestige Consumer Healthcare by 547.4% during the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after acquiring an additional 520,186 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of Prestige Consumer Healthcare by 107.9% during the 4th quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock valued at $34,639,000 after acquiring an additional 291,425 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Prestige Consumer Healthcare by 316.1% during the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after acquiring an additional 229,311 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Up 1.9%

PBH stock opened at $48.64 on Wednesday. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $87.12. The company has a fifty day simple moving average of $52.61 and a 200 day simple moving average of $59.82. The firm has a market cap of $2.30 billion, a PE ratio of 12.44, a PEG ratio of 1.53 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period in the previous year, the firm posted $1.32 EPS. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PBH. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Canaccord Genuity Group lowered their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).